Noven Pharmaceuticals’ Secuado (asenapine) transdermal system received the FDA’s approval for treating adults with schizophrenia.

The once-daily transdermal drug delivery system gives sustained concentrations of the antipsychotic asenapine. The medication has been approved by the FDA for treating adults with schizophrenia and manic or mixed episodes stemming from bipolar I disorder.

The transdermal patch formulation, the first of its kind, is designed to assist patients in alleviating some of the challenges associated with managing the disorder.